Abolis raises €35 million, forms development pact with Evonik and L’Oréal
In Germany, Abolis Biotechnologies has closed a €35 million ($38.9 million) financing round to scale its biomanufacturing operations, accelerate business development efforts, develop its own line of products, and expand the activities of Microbiome Studio, its business unit dedicated to deciphering and engineering microbial ecosystems. Participants in the funding round include Evonik Venture Capital; BOLD, […]
